Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Long-term CZP treatment for axSpA yields sustained cuts in inflammation, limits progression

10 Mar 2018

In patients with axial spondyloarthritis (axSpA), early improvements in inflammation achieved with certolizumab pegol (CZP) may be maintained for up to 204 weeks, with a decreased rate of spinal progression between years 2 and 4, according to a study.

A total of 325 patients were randomized to receive either placebo (n=107) or CZP (200 mg Q2W: n=111; 400 mg Q4W: n=107). The study was placebo-controlled and double-blind until week 24, dose-blind to week 48 and open-label to week 204.

There were 315 patients (174 had ankylosing spondylitis [AS] and 141 had nonradiographic [nr]-axSpA) who received ≥1 dose CZP at any point in the trial, with 199 completing the study to week 204 and 158 having valid magnetic resonance imaging (MRI) assessments at baseline.

MRI improvements in inflammation from baseline to week 12 were sustained to week 204. The Spondyloarthritis Research Consortium of Canada (SPARCC) score for sacroiliac (SI) joints decreased from 8.5 to 1.3 in the AS subgroup and from 7.5 to 2.4 in the nr-axSpA subgroup. The Berlin spinal score also dropped from 7.4 to 2.6 in the AS subgroup and from 4.4 to 1.9 in the nr-axSpA subgroup.

Remission was achieved at week 204 in 66.7 percent of patients with AS and 69.6 percent of those with nr-axSpA having SPARCC scores ≥2 at baseline, and in 65.4 percent of patients with AS and 57.3 percent of those with nr-axSpA having Berlin scores >2 at baseline.

Mean modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) changes in the AS subgroup were 0.98 from baseline to week 204, 0.67 from baseline to week 96, and 0.31 from week 96 to week 204. Corresponding mSASSS changes in the nr-axSpA subgroup were 0.06, –0.01 and 0.07.

At week 204, 4.5 percent of patients with nr-axSpA subgroup fulfilled the modified New York criteria, while 4.3 percent of patients with AS no longer did so.

The present data demonstrate the long-term efficacy of CZP in the treatment of axSpA, with a rapid reduction in inflammation, sustained rates of remission in both SI joint and spinal examinations, reduced rate of spinal progression, and limited SI joint progression during the 4 years of study, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.